Deutsche Bank AG vs Roivant Sciences Ltd. Common Shares — how do they compare? Deutsche Bank AG trades at $33.69 (market cap $62.42B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Deutsche Bank AG is far larger — about 2.5× Roivant Sciences Ltd. Common Shares's market cap, and Deutsche Bank AG pays a 3.46% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| DB | ROIV | |
|---|---|---|
Market Cap | $62.42B | $24.72B |
Volume | 2,918,760 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $41.56 | $41.81 |
52-Week Low | $28.37 | $16.04 |
Typical Hold Time | 80 Days | 1 Days |
Enterprise Value | $77.06B | $20.99B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.68, up 0.39% today, with a bearish technical signal from moving averages but recent earnings beats. The stock shows attractive valuation with a P/E of 9.09 and P/B of 0.71, while net income surged to $6.93B in 2025. News highlights include strategic appointments and a raised 2026 net interest income outlook, though Q3 investment banking revenue is expected to be flat to slightly down.
The outlook is mixed: strong fundamentals and cost-saving initiatives support growth toward 2028 targets, but bearish technicals and a high proportion of hold ratings suggest near-term caution. Key risks include volatile investment banking revenue and macroeconomic pressures, while institutional sentiment remains divided with 57.58% hold ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →